Many Cancer Drugs Fail to Prove Benefits Within Five Years of Accelerated Approval

The U.S. Food and Drug Administration's (FDA) accelerated approval program, initially established in 1992 to hasten the availability of HIV medications, has predominantly shifted its focus towards cancer drugs, with 85% of its expedited approvals now dedicated to them. This program permits the FDA to fast-track drugs showing potential benefits for treating serious or life-threatening diseases, granting patients earlier access. However, a recent study raises concerns about the effectiveness of these drugs, revealing that a significant number do not prove their worth within five years of receiving accelerated approval.

Published in the Journal of the American Medical Association and presented at the American Association for Cancer Research annual meeting in San Diego, the study scrutinized 46 cancer drugs that received accelerated approval between 2013 and 2017. Findings indicated that while 63% of these drugs were eventually granted regular approval, only 43% showed clinical benefits in subsequent confirmatory trials. This discrepancy underscores a critical gap in the accelerated approval process, questioning the program's ability to ensure that these drugs provide real value to patients battling cancer.

Implications for Patient Care

The study's co-author, Dr. Edward Cliff of Harvard Medical School, pointed out the potential lack of awareness among cancer patients regarding the uncertainties associated with drugs approved through this expedited process. The need for transparency in communicating these uncertainties to patients was echoed by Dr. Jennifer Litton of MD Anderson Cancer Center in Houston. She emphasized the importance of doctors not overpromising on the outcomes, which might range from tumor shrinkage to stability duration.

Recent Reforms and FDA's Enhanced Authority

In response to growing concerns about the accelerated approval pathway, Congress recently amended the program to grant the FDA increased authority, particularly in withdrawing drugs that fail to meet their post-approval obligations. According to FDA spokesperson Cherie Duvall-Jones, these changes facilitate a more efficient process for removing drugs that do not confirm their initial promise. Additionally, the FDA now mandates that a confirmatory trial be in progress at the time of granting preliminary approval, aiming to expedite the verification of a drug's effectiveness.

Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research, criticized the current state of affairs where thousands of patients receive drugs without conclusive evidence of their efficacy. The study's findings and subsequent regulatory changes highlight an ongoing effort to refine how promising treatments are introduced to patients, ensuring they offer tangible benefits without undue delay.